Maze Therapeutics Inc. (MAZE)
| Bid | 9.12 |
| Market Cap | 400.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | 0.08 |
| PE Ratio (ttm) | 114.19 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 9.16 |
| Volume | 211,140 |
| Avg. Volume (20D) | 332,645 |
| Open | 8.43 |
| Previous Close | 9.32 |
| Day's Range | 8.33 - 9.25 |
| 52-Week Range | 8.33 - 17.00 |
| Beta | 0.00 |
About MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of ...
Analyst Forecast
According to 3 analyst ratings, the average rating for MAZE stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 206.51% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOsFive IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK T...
